Pharma CEOs vs. PBMs at the Senate HELP hearing

Originally posted February 19, 2024 by Chris Vanderwolk

Pharma CEOs vs PBMs - The Real Culprits Behind High Drug Prices? 🤔

Recently, top pharma executives were grilled in a Senate hearing about soaring drug prices. Their defense? Pointing fingers at pharmacy benefit managers (PBMs). While it's no secret that drug prices are sky-high, the blame game between pharma companies and PBMs is heating up.

Are pharma CEOs shifting blame to sidestep responsibility, or are PBMs the hidden manipulators in this high-stakes game? What's your take on this tug-of-war impacting our healthcare costs?

Originally posted on LinkedIn, where the discussion and source links live in the comments.

About the author

Chris Vanderwolk is Director of Compliance and Innovation at OneDigital | Kistler Tiffany Benefits General Agency, where he helps brokers and employers navigate the regulatory complexity of employee benefits. An ERISA attorney with more than 19 years in the benefits industry, he specializes in translating what the law actually requires into language people can use.